[
  {
    "ts": null,
    "headline": "Edwards Lifesciences Corporation (EW) Draws Positive Analyst View After Q4 Update",
    "summary": "Edwards Lifesciences Corporation (NYSE:EW) is one of the best medical technology stocks to invest in. On February 11, Stifel reiterated its Buy rating on Edwards Lifesciences and kept its price target at $110. Stifel made the move right after Edwards Lifesciences shared its Q4 2025 earnings on February 10. The results showed that quarterly sales […]",
    "url": "https://finnhub.io/api/news?id=e6807a3aebd4680586849816b9cb9ece6b0be2d261ac657a34fe12b33d0c956b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771156376,
      "headline": "Edwards Lifesciences Corporation (EW) Draws Positive Analyst View After Q4 Update",
      "id": 139105979,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Edwards Lifesciences Corporation (NYSE:EW) is one of the best medical technology stocks to invest in. On February 11, Stifel reiterated its Buy rating on Edwards Lifesciences and kept its price target at $110. Stifel made the move right after Edwards Lifesciences shared its Q4 2025 earnings on February 10. The results showed that quarterly sales […]",
      "url": "https://finnhub.io/api/news?id=e6807a3aebd4680586849816b9cb9ece6b0be2d261ac657a34fe12b33d0c956b"
    }
  },
  {
    "ts": null,
    "headline": "Can JPMorgan’s Downgrade Reshape AtriCure’s (ATRC) Competitive Moat In Cardiac Surgery Devices?",
    "summary": "AtriCure recently faced a shift in analyst sentiment when JPMorgan downgraded the company to Neutral, citing rising competitive pressure on its AtriClip device from Edwards Lifesciences’ planned surgical offering. This change highlights how competition in cardiac surgery devices can quickly alter perceptions of AtriCure’s positioning, even as other analysts maintain positive views on its prospects. We’ll now examine how JPMorgan’s concerns about Edwards Lifesciences’ competitive threat could...",
    "url": "https://finnhub.io/api/news?id=b7c76715ad92688d3afdeb1ddbd718aa81ff53333b57691fcf9b34df2558c8c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771146768,
      "headline": "Can JPMorgan’s Downgrade Reshape AtriCure’s (ATRC) Competitive Moat In Cardiac Surgery Devices?",
      "id": 139105302,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "AtriCure recently faced a shift in analyst sentiment when JPMorgan downgraded the company to Neutral, citing rising competitive pressure on its AtriClip device from Edwards Lifesciences’ planned surgical offering. This change highlights how competition in cardiac surgery devices can quickly alter perceptions of AtriCure’s positioning, even as other analysts maintain positive views on its prospects. We’ll now examine how JPMorgan’s concerns about Edwards Lifesciences’ competitive threat could...",
      "url": "https://finnhub.io/api/news?id=b7c76715ad92688d3afdeb1ddbd718aa81ff53333b57691fcf9b34df2558c8c5"
    }
  }
]